Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer.
PHI
PHI density
biopsy
multiparametric magnetic resonance imaging
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Sep 2021
21 Sep 2021
Historique:
received:
05
08
2021
revised:
16
09
2021
accepted:
18
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Widespread use of PSA as the standard tool for prostate cancer (PCa) diagnosis led to a high rate of overdiagnosis and overtreatment. In this study, we evaluated the performance of the prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the prediction of positive biopsy and of high-grade PCa at radical prostatectomy (RP). To this end, we prospectively enrolled 196 biopsy-naïve patients who underwent mpMRI. A subgroup of 116 subjects with biopsy-proven PCa underwent surgery. We found that PHI significantly outperformed both PI-RADS score (difference in AUC: 0.14;
Identifiants
pubmed: 34572950
pii: cancers13184723
doi: 10.3390/cancers13184723
pmc: PMC8466029
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Università degli Studi di Napoli Federico II
ID : FRA 2020 linea B
Références
Eur Urol. 2020 Aug;78(2):163-170
pubmed: 32370911
Clin Chim Acta. 2020 Feb;501:174-178
pubmed: 31758936
Abdom Radiol (NY). 2020 Dec;45(12):4178-4184
pubmed: 33048224
Int J Mol Sci. 2021 Jun 10;22(12):
pubmed: 34200878
Diagnostics (Basel). 2021 Feb 20;11(2):
pubmed: 33672608
Eur J Radiol. 2019 Jul;116:144-149
pubmed: 31153556
BJU Int. 2015 May;115(5):728-35
pubmed: 25041307
Urologia. 2021 Jun 2;:3915603211019982
pubmed: 34075837
Int J Mol Sci. 2020 Feb 11;21(4):
pubmed: 32053990
Anticancer Res. 2015 Feb;35(2):1017-23
pubmed: 25667489
Transl Res. 2014 Dec;164(6):444-51
pubmed: 25035153
Diagnostics (Basel). 2021 Feb 18;11(2):
pubmed: 33670632
Transl Androl Urol. 2018 Feb;7(1):70-82
pubmed: 29594022
Clin Biochem. 2010 Jul;43(10-11):926-8
pubmed: 20450900
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
World J Urol. 2021 Jun;39(6):1889-1895
pubmed: 32761380
Life (Basel). 2021 Apr 07;11(4):
pubmed: 33917253
BMC Med. 2020 Apr 17;18(1):95
pubmed: 32299423
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):78-84
pubmed: 29158509
PLoS One. 2013 Jul 04;8(7):e67687
pubmed: 23861782
Eur Radiol. 2021 Oct;31(10):7575-7583
pubmed: 33792737
Curr Opin Urol. 2021 Jul 1;31(4):416-423
pubmed: 33965983
Sci Rep. 2021 Mar 5;11(1):1286
pubmed: 33674631
Cancers (Basel). 2020 Dec 16;12(12):
pubmed: 33339117
World J Urol. 2021 Feb 15;:
pubmed: 33590279
BJU Int. 2020 Sep;126(3):373-378
pubmed: 32367635
Eur Urol. 2020 Sep;78(3):402-414
pubmed: 32444265
J Endourol. 2017 Nov;31(11):1111-1116
pubmed: 28797178
Clin Chem Lab Med. 2013 Apr;51(4):729-39
pubmed: 23154423
Clin Chim Acta. 2012 Aug 16;413(15-16):1274-8
pubmed: 22542564
BJU Int. 2018 Apr;121(4):619-626
pubmed: 29232037
Urol Int. 2021;105(9-10):804-810
pubmed: 34247169
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Sci Rep. 2016 Oct 17;6:35364
pubmed: 27748407
World J Urol. 2020 May;38(5):1207-1214
pubmed: 31440806
Prostate Cancer Prostatic Dis. 2017 Jun;20(2):228-233
pubmed: 28117387
JAMA. 1994 Feb 2;271(5):368-74
pubmed: 7506797
Nat Rev Urol. 2021 Apr;18(4):197-208
pubmed: 33623103
Prostate. 2013 Feb 15;73(3):227-35
pubmed: 22821756
Nat Rev Urol. 2013 Aug;10(8):473-82
pubmed: 23712205